Immune System Key Ltd.

Immune System Key Ltd. was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary. It is a privately held company, engaged in discovery and development of innovative treatments for malignant and autoimmune diseases with strong unmet needs. Its assets are based on novel human secreted peptides, which were discovered by the founders. ISK’s lead compound is NerofeTM. NerofeTM was granted by the FDA with orphan drug status for AML treatment. The company is now in preparation for phase IIa. The company holds 3 worldwide patents on the molecule and applications.

LATEST NEWS

  • _A0A0227

PMWC 2018 conference – New Technology Presented

04 Feb|Comments Off on PMWC 2018 conference – New Technology Presented

At  PMWC 2018 conference Dr. Yoram Devary presented ISK new technology dealing with “personalized ImmunoOncology therapy” 

New Article Published: Nerofe Phase I trial summary

11 Dec|Comments Off on New Article Published: Nerofe Phase I trial summary

The Phase I Nerofe (dTCApFs) human trial summary has been published in the Molecular and Clinical Oncology Journal.

In this trial Nerofe was found to be safe and well‑tolerated, and potentially efficacious as an anti-cancer agent.